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indicate DFA administration as therapy for patients at risk of Al
toxicity.
Hepatitis with Captopril treatment. J. P. Rycke!ynck, J. M. Batho, J.
Peny, D. Grach, P. Beuve-Mery. Service de Nephrologie et d'Hémo-
dialyse, CHRU Caen, France. A patient developed anicteric hepatitis
while being treated with Captopril (SQ 14 225). To date, only one case
with hepatic involvement during Captopril administration has been
reported. A 36-year-old woman with hypertension and end-stage renal
failure treated by hemodialysis received 50 mg Captopril four times
daily for 20 months. Every 3 months liver function tests were made;
these were normal until March 1981. At this time, the patient became
tired and complained of pruritus. On examination, there was no
abnormal sign. However, SGOT was 400 units• l (normal up to 18)
SGPT 550 units 1' (normal up to 21). Total bilirubin and alkaline
phosphatase were normal. Serum radioimmunoassays for hepatitis B
surface antigen (HBsAg) and for antibody to hepatitis A were negative,
as were complement fixing antibody titres to infective mononucleosis
and cytomegalovirus. A liver biopsy was performed which showed
lesions of hepatitis. Captopril therapy was discontinued and liver
disorders disappeared. Three weeks later, Captopril was re-introduced
in 50 mg twice daily; SGOT SGPT again rose. The results of this re-
introduction test allow the incrimination of this therapy in the genesis of
hepatic cytolysis.
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Clinical Relevance of N-acetyl-glucosaminidase determination in renal
allograft recipients immunosuppressed conventionally or by Cyclosporin
A. R. Loertscher, F. P. Brunner, G. Thiel. Nephrologie Abteilung,
Departement für Innere Medizin, Universität Base!, Switzerland. N-
acetyl-glucosaminidase (NAG) was monitored daily for 60 days in 25
recipients of an allograft between January and September 1981. Twelve
of these patients were treated by Cyclosponn A (CyA), 13 by conven-
tional immunosuppression with azathioprin and prednisone. NAG was
indicated as ratio NAG U/liter to urine creatinine mmoles/liter. The
purpose of these determinations was to evaluate NAG as an early
predictor of graft rejection and to estimate NAG excretion as indicator
for CyA toxicity. Rejection was assessed either clinically or by graft
biopsy (24 biopsies in 16 patients). CyA toxicity was estimated by
clinical signs, biochemical parameters (liver enzymes), CyA serum
trough level determinations, and graft biopsies. NAG excretion in both
groups did not correlate consistently with graft rejection. NAG determi-
nation did not help to establish this diagnosis. Different NAG profiles
showed the wide variation of NAG excretion. Only in single cases a
close correlation was found with postrenal obstruction and CyA serum
trough levels.
Fatal complications in kidney allotransplant recipients. G. Keusch, A.
Burgier, G. Uh!schmid, J. Briner, F. Largiader, U. Binswanger.
Medizinische und Chriurgische K!inik A, Inst itut fur Pathologie, Uni-
versitãtsspita! Zurich, Switzerland. At the university hospital of Zurich
523 patients (mean age 44 7 (SD) years, ranging from 7—60 years)
received 605 kidney allotransplants between November 1964 and Au-
gust 1980. During this period 193 deaths occurred and the causes of
death could be analyzed in 167 patients (86.5%) by hospital records and
autopsy findings. In 98 patients (58.7%) the kidney graft was still
functioning at the time of death. Forty-four percent of all deaths
occurred during the first 3 months following transplantation. Causes of
death included: Infections in 74 patients (44.3%); cardiovascular com-
plications in 30 patients (18%); cerebrovascular accidents in 13 patients
(7.8%); gastroduodenal complications in 11 patients (6.6%) and malig-
nancies in 14 patients (8.4%). Forty of 74 (54%) lethal infections
occurred during the first 3 months following transplantation. Bacterial
organisms (68% gram negative germs) accounted for 46%, viruses (73%
cytomegalo-viruses) for 27%, fungi for 15%, and parasitic organisms for
4% of the infections. The most frequently affected organs were the
lungs (73%), the gastrointestinal tract (43.2%), and the central nervous
system (23%). The incidence of viral and fungal infections showed a
maximum in the second and third post-transplant month. Lethal cere-
bro- and cardiovascular complications occurred either in the early
(within 3 months) or late (>2 years) post-transplant period. Malignan-
cies were a typical fatal complication in the late period following
transplantation including four fatal cases of solid lymphomas. Of the 11
patients with fatal gastrointestinal complications seven patients died as
a result of gastrointestinal ulcers. Data from this study showed that in
cadaveric kidney recipients infections were the leading cause of death,
occurring most frequently within the first 3 months and the predominate
site of infections were the lungs.
Renal replacement therapy in diabetics: A comparative analysis of
CAPD, hemodialysis, and cadaveric kidney transplantation. S. Peter, G.
Keusch, F. Bammatter, F. Largiader, U. Binswanger. Medizinische
und Chriurgische K!inik A, Universitdtsspital Zurich, Switzerland.
Thirty-four juvenile onset diabetic patients (mean age 39.4 10.1 (SD)
years) with end-stage renal failure were treated by the following renal
replacement therapy: CAPD in 13 patients (mean age 44.8 11.3
years), hemodialysis in 8 patients (39.8 9.8 years), and cadaveric
kidney transplantation in 13 patients (33.8 5.7 years). The follow-up
during 1.5 to 40.5 months (total patient-months 422.5) revealed 17
deaths. Nine deaths occurred at 6 months and 14 at 1 year, respectively.
The mortality and causes of death in the different treatment modalities
were as follows:
Mortality
at 6 months at 1 year at 2 years
CAPD
Hemodialysis
Transplantation
4/10 (40%)
2/8 (25%)
3/12 (25%)
5/6 (83%)
5/5 (100%)
4/10 (40%)
6/6
6/10
(100%)
—
(60%)
Causes of death
Infection
Cerebro- and cardio-
vasc. complications Others
4 1 1
0 5 —
2 3 1
CAPD
Hemodialysis
Transplantation
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The leading causes of death were cerebro- and cardiovascular complica-
tions and predominately bacterial infections. The patients survival was
poor and essentially the same at 6 months in the different treatment
modalities but tended to improve at 1 year in kidney transplant
recipients.
Renal cholesterol-embolization: Report of three cases. W. Tenschert,
F. W. Reutter, and M. Burgin. Medizinische Klinik B und Institut für
Pathologie, Kantonsspital Si. Ga/len. Renal cholesterol-embolization
(RCE) may occur spontaneously or after great vessel surgery or arterio-
graphy. It occurs most frequently in males aged over 60 years with
advanced arteriosclerosis. Diagnosis is made by the presence of needle-
shaped cholesterol crystals in the renal vasculature. Three cases of
RCE are presented diagnosed by renal biopsy in case I and autopsy in
cases 2 and 3.
Patient Clinical diagnosis Laboratory data
Case 1, 67 yr Renal art. stenosis Sed. rate , eosinophilia,
Hypertension proteinuria, hematuria
Case 2, 61 yr Bilat. renal art. stenosis Sed. rate , eosinophilia,
Moderate renal failure creatinine , proteinuria,
hematuria
Case 3, 76 yr Hypertension Sed. rate , eosinophilia,
Ulcerous arteriosclerosis proteinuria, hematuria
RCA initiating Documentation
Case procedure Clin. course of CE
I Renal arteriography Renal failure Renal biopsy
or spontaneous Hypertension Fundusscopy2 Renal arteriography Renal failure t Autopsy
Hypertension
3 Spontaneous Renal failure t Muscle biopsy
Hypertension, myocar- Autopsy
dial infarction
Hypertension of two patients could be well controlled by Captopril.
Although significant RCE is a rare complication of generalized arterio-
sclerosis, it should be considered as a possibility in patients with severe
arteriosclerosis with decreasing renal function and acceleration of
hypertension occurring after great vessel surgery or angiography.
Renal clearance of catecholamines in man. L. Link, P. Weidmann, C.
Bereita-Piccoli, K. Boehringer, H. Schiffi, and F. C. Reubi. Medizin-
ische Poliklinik, University of Berne, Switzerland. The adrenergic
system interacts with a variety of tissues and organs, including the
kidney. However, little is known about the renal clearance of norepi-
nephrine (NE) and epinephrine (E) in man. To obtain this information
18 normal subjects were studied (N) (6 females, 12 males, mean age 25
5 (±st) yr), seven patients with untreated benign essential hyperten-
sion (EH) (4 females, 3 males, mean age 57 6yr) and 10 patients with
renal parenchymal disease (RPD) (5 females, 5 males, mean age 43 13
yr). Glomerular filtration rate and effective renal plasma flow (by
constant infusion clearance technique using 51Cr-EDTA and PAH,
respectively), as well as plasma and urinary NE and E concentrations
(by the radioenzymatic assay of Da Prada) were measured simulta-
neously. With the latter method the recoveries of NE and E were
similar in plasma and urine (20% for NE, 25% for E). The results are
shown in the table:
Plasma
Renal clearance
ml/min/1.73 m2
concentration
ng/dl
£ NE EPAH 51Cr-EDTA NE
N 601 133 118 14 115 42 395 187 28 12 3.7 1.7
EN 414 87 103 15 III 61 265 213 29 8 3.5 1.6
RPD 411 165 86 43 89 32 285 272 35 8 6.7 4.6
These findings indicate that in normal subjects as well as in patients
with benign essential hypertension or early stage renal parenchymal
disease, the renal clearance of NE closely corresponds to the glomeru-
lar filtration rate. Moreover, because the clearance of E markedly
exceeded the glomerular filtration rate, active tubular secretion of E
seems to occur in the human kidney.
Oxaluria in idiopathic recurrent stone formers in Switzerland. P.
Jaeger, P. Burckhardt, and A. F. Jacquet. Department of Internal
Medicine, C.H. U. V. Lausanne, Switzerland. Hyperoxaluria is regard-
ed generally as a major risk factor of urinary calcium precipitation, but
the incidence of mild hyperoxaluria among recurrent stone formers is
still a matter of debate. To investigate this latter aspect of renal stone
disease, urinary oxalate excretion (Uox V) was measured in 57
patients with idiopathic recurrent calcium urolithiasis. There were 41
males and 16 females, aged 18 to 72 (mean 46 yrs); the group consisted
of 21 patients with idiopathic hypercalciuria of the renal type (R-IHC),
15 patients with that of the absorptive type (A-IHC), and 21 cases
without hypercalciuria (No IHC): Classification was based upon the
rate of urinary calcium excretion (UCa V) obtained on a regular
patient's diet (Reg), after 3 days on a calcium-enriched diet (+ 3 g/d)
(high CA), and after 5 days on a diet completely deprived of dairy
products (low Ca). Uox' V was measured by colorimetry (chromotropic
acid) in the three dietetic conditions, and results were compared with
those obtained in 29 normal subjects, as below (mean SEM, 1imole/d).
Paired-i
Reg High Ca Low Ca
(Low Ca
vs. Reg)
Controls 319 15 326 13 359 17 p < 0.025
R-IHC 340 24 340 19 415 35 p < 0.0125
A-IHC 327 15 353 20 395 27 p < 0.01
No IHC 343 20 363 33 335 27 NS
Normal range of oxaluria on a regular diet was 125 to 440 moles/d, and
an elevated value was found in only five patients (that is, two with R-
IHC and three without IHC). After low Ca diet, a significant increase in
mean oxaluria was detected in controls and in both groups of IHC; on
this diet, mild hyperoxaluria (that is > 440 moIes/d) was present in 2 of
29 controls, in 7 of 21 patients with R-IHC, 6 of 15 with A-IHC and 4 of
21 without IHC. In conclusion, on a regular diet, mild hyperoxaluria
occurs in only 10% of the whole population of idiopathic recurrent stone
formers; more importantly, this disorder is found in about 15% of the
patients usually classified by others as having "no metabolic disorder."
On a low Ca diet, mild hyperoxaluria can be observed in controls as
well as in any type of the patients, especially in patients with absorptive
IHC; hence, suppression of dairy products only, might not be useful for
stone formers.
Treatment of peritonitis in patients undergoing CAPD. P. Glasson, H.
Favre, and M. Leski. Division de Nephrologie, Département de Méde-
cine, Hôpital Cantonal Universitaire, Genève, Suisse. Occurrence of
peritonitis has hindered the development of CAPD and controversy has
risen regarding their treatment (T). Simple and ambulatory T has been
used in our 20 CAPD patients (270 patient/month) who experienced 32
episodes of peritonitis with positive culture. Intraperitoneal Co-Trimox-
azole (80 mg Trimethoprim and 400 mg sulfametoxazole) with 1000 U
heparin was added to the four daily bag during 2 weeks and to 2 of them
during 2 other weeks. Results: 47% of peritonitis was due to staph.
aureus of which 100% were sensitive to Co-trimoxazole, 37% due to
staph. epidermidis of which 75% were sensitive to Co-trimoxazole, 16%
due to other germs (corynebacterium, strepto sp., proteus, pseudomo-
nas) of which 60% were sensitive. Three non-sensitive germs were
treated with Co-trimoxazole successfully. Hospitalization and treat-
ment using a peritoneal dialysis machine (hourly dialysate fluid ex-
changes) was necessary in only three cases. No death or other
complications were observed. In conclusion, (1) Peritonitis can suc-
cessfully be treated with such a scheme, ambulatory; (2) 85% of all the
germs are sensitive to Co-trimoxazole; (3) some of the nonsensitive
germs may be treated with Co-trimoxazole when a good clinical
response is obtained; (4) other germs (mainly gram-negative germs) may
require either specific antibiotherapy with or without peritoneal dialysis
machine.
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Acute lower abdominal pain occurring at the start of a hemodialysis
session. J. P. Wauters, E. Buchser, P. Hotz, and J. J. Boil/at. Divisions
of Nephrology, Anesthesiology and Urology, University Hospital,
Lausanné, Switzerland. Acute bilateral lumbar pain at the start of a
hemodialysis session has been recognized as a dialysis-induced syn-
drome related to abrupt reduction in blood volume. By reducing
extracorporeal blood volume during dialysis and/or decreasing blood
flow this syndrome is considerably or totally reversed. A similar
syndrome was observed hitherto not described also occurring exclu-
sively at the start of a hemodialysis session. Four patients, aged 36 to 74
years, I male and 3 females, on chronic hemodialysis for at least 14
months complained of an excruciating pain in the suprapubic area of
sudden onset a few seconds after the start of a dialysis session. A few
minutes later the pain disappeared spontaneously and did not reappear
until the next dialysis session. No other symptoms were noted and
clinical examination was unrevealing. No drop in blood pressure
occurred before or during the pain. The reduction of extracorporeal
blood flow or the use of pediatric blood lines was ineffective. However,
in each case the presence of an urinary tract infection due to Escherich-
ia coli and Kiebsiella was demonstrated. No other symptoms or signs of
urinary tract infection could be found. Residual diuresis was between 10
and 400 ml/24 hr. A relationship between urinary tract infection and the
paroxysm of pain was strongly suggested by the fact that treatment of
infection cured the pain in three patients whereas in one the infection
due to a pyelal calculus could not be controlled. In this case, the vesical
instillation of procain hydrochloride 0.4% brought some relief of the
pain. These observations show that in chronically hemodialyzed pa-
tients acute lower abdominal pain occurring exclusively at the start of a
hemodialysis session can be the only manifestation of a urinary tract
infection. This suggests that hemodynamic factors combined with
inflammatory processes play a role in the genesis of the pain.
Continuous ambulatory peritoneal dialysis (CAPD) in pediatric pa-
tients: Two years' experience. C. He//er-A ckeret, W. Ertelt, and E. P.
Leumann. Univ.-Kinderklinik, Zurich, Switzerland. Four children aged
6—10 years (body weights 20 to 31 kg) and one adolescent patient (age 17
years; 32 kg) were treated by CAPD over periods of 3 to 10 months.
Adult Tenckhoff catheters were implanted except in one instance.
Volumes of 1 liter (1.5 1 in the oldest patient) were exchanged four times
a day. The dialysate contained glucose 15 g/liter during three (occasion-
ally two) cycles, and 42.5 g/liter during one (or 2) cycles. Results:
Overall patients' acceptance was good. One patient is still on CAPD,
three had a renal transplant, and in one, renal function recovered.
Rehabilitation was good, but full school attendance was not achieved in
two children. Peritonitis was observed five times. However, its inci-
dence fell from one episode every 5 months in 1979/80 to one every 10
months in 1980/81 concomitant with improved dialysis technique.
Erosion of the Dacron cuff occurred twice. One catheter was pulled out.
Protein losses in the dialysate were 0.10 to 0.17 glkg per day in four
children; their serum protein was 5.7 to 6.9 g/dl. One child with sterile
peritonitis lost 0.46 g protein per kg and day and became frankly
hypoproteinemic (4.7 g/dl). Average serum values of BUN were 60 mg/
dl and of creatinine, 6.5 to 8 mg/dl. Statural growth was poor in the two
children treated over 10 months. Conclusions: CAPD offers a valuable
alternative to hemodialysis in selected pediatric patients. However,
growth retardation is disturbing, and the long-term potential of CAPD
remains to be demonstrated.
Effects of piretanide compared with furosemide in renal insufficiency.
C. Marone and F. C. Reubi. Ospedale San Giovanni, Bellinzona and
Medizinische Universitáts-Poliklinik, Bern, Switzerland. The diuretic
effect of the new drug piretanide was investigated in patients with renal
insufficiency and compared with furosemide. In a first study four
hospitalized patients (serum creatinine 4.6 to 13.8 mg/dI) were exam-
ined after oral administration of piretanide (given every third day in a
dose of 12, 24, 48, and 96mg to two patients and 24, 48, 96, and 192 mg
to the remaining two). In the second study six patients (serum creati-
nine 2.2 to 7.9 mg/dl) received an oral dose of pirentanide (48 and 96mg)
or furosemide (160 and 320 mg) every fourth day. Twenty-four-hr urine
was collected every day and sodium and potassium excretion were
measured. The natriuretic effect of 48 and 96 mg of piretanide averaged
250 and 340% of control. The effect was especially marked in the
subgroup with creatinine level less than 6.0 mg/dl. With each dose, a
linear inverse correlation was found between the logarithm of natriure-
sis and serum creatinine level (Iny —0.614 lnx + 6.51, r =
—0.879, P
<0.001, with 48 mg). At a given serum creatinine level, the natriuretic
response was dependent on the administered dose, but the dose-
response curve was less steep when impairment of renal function was
severe. The drug was less effective on water and potassium diuresis
than on natriuresis. Compared with furosemide given in a ratio furose-
mide/piretanide of 3.33/liter no significant differences were found in
natriuresis, kaliuresis and water diuresis in renal insufficiency. Results
demonstrate that the natriuretic effect of piretanide is potent and still
present even in severe renal insufficiency. However at the dosage used
no significant differences were found between the two diuretics exam-
ined when the drugs were given in a ratio furosemide/piretanide of 3.33/
liter.
Altered prednisolone kinetics in patients with nephrotic syndrome. F.
J. Frey and B. M. Frey. Medizinische Poliklinik, Inst it ut für Klinische
Pathologie and Inst it ut für Klinische Pharmako/ogie, Universität Bern,
Switzerland. The purpose of the study was to quantify the impact of
nephrotic dysproteinemia on prednisolone kinetics. Prednisolone (P)
was given iv. (0.78 mg/kg) to six patients with nephrotic syndrome and
to II healthy volunteers. Following dosing, blood samples were collect-
ed over a 24-hr period. Total and unbound P concentrations in plasma
were assessed by high performance liquid chromatography and by
equilibrium dialysis. The concentrations of transcortin were determined
by electroimmunodiffusion. The plasma clearances of total P and
unbound P were calculated as the dose of P given divided by the area
under the plasma concentration time curve of total P (AUCT) or of
unbound P (AUC). The mean free fraction of P was calculated by
dividing the AUC by the AU CT. The mean residence time of P in the
body was calculated by dividing f tcdt by the AUCT, where c,
concentration of P; t, time. The volume of distribution of P was
calculated by multiplying the mean residence time by the clearance of
P. The results ( SD) were the following:
Subjects Volunteers Nephrotic patients P
Transcortin (mg/liter) 45 6.9 20 5.7 <0.001
Unbound fraction
of P 0.26 0.02 0.36 0.03 <0.001
Total P clearance
(ml/min.kg) 2.5 0.3 3.3 0.5 <0.005
Unbound P clearance
(mlIminkg) 9.7 1.6 9.1 1.0 NS
Mean residence time
of P (mm) 253 33 249 34 NS
Volume of distribu-
tion of total P
(liter/kg) 0.64 0.07 0.84 0.17 <0.01
The unbound fraction of P decreases with increasing plasma concentra-
tion of transcortin (r = 0.87; P < 0.001). The total P clearance increases
as a function of the unbound fraction of P (r = 0.75; P < 0.002).
Conclusion: Probably as a consequence of low transcortin concentra-
tions, patients with nephrotic syndrome have lower total P concentra-
tions in plasma than healthy volunteers, but normal unbound P concen-
trations in plasma and normal total amounts of P in the body.
Ca-P metabolism is particularly disturbed in analgesic abuse nephrop-
athy (AAN), P. Jaeger, P. Burckhardt, and J. P. Wauters, Department
of Medicine, University Hospital, Lausanne, Switzerland. Ca-P metab-
olism was evaluated in two groups of patients with chronic interstitial
nephritis: in 21 patients (AAN-group), nephropathy was due to expo-
sure for 5 to 50 years (mean 21. 1) to phenacetin-containing analgesics,
whereas in 21 other patients (controls), it was due to exposure for 1 to
80 years (means 21 .4)(NS) to other causes. Patients were followed for
2,5 0.6 and 1.6 0.6 years, respectively (mean sEM)(NS). In each
patient, blood Ca, P, protein, creatinine, alkaline phosphatase, PTH,
and arterial acid-base status were determined serially and then averaged
for two degrees of renal failure, that is, for creatinine levels < or >400
lJ.M. Results were included only when P was normal or maintained close
to normal (that is, 0.7 to 1.9 mM) with help of phosphate-binding
antacids. Mean blood creatinine, P, protein and acid-base status were
not significantly different in AAN- and control groups at each creatinine
subdivision. Differences were:
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Creatinine LM Ca miii PTH ng/ml Alk.P lU/liter
<40° AANControls
2.19 0.06**
2.34 0.02
0.34 0.06**
0.23 0.02
37
30
6
2
>400 AANControls
1.90 0.06***
2.19 0.03
0.90 0.14*
0.36 0.13
65
34
12*
4
* P < 0.05, ** p < 0.025, P <0.005 (AAN vs. controls)
In addition, significant linear relationships were observed between Ca
and creatinine, PTH and creatinine, PTH and Ca, and Alk.P and PTH;
in the first two cases, the slope of the regression line obtained in AAN
was significantly different from controls, confirming differences de-
scribed above, over the whole range of creatinine levels studied (95 to
1600 PM). Conclusion: At comparable stages and durations of renal
failure, patients with AAN, when compared with patients with intersti-
tial nephritis of other origin, have lower blood Ca and consequently
higher PTH and alkaline phosphatase levels, suggesting more severe
vitamin D deficiency and osteodystrophy.
Inhibition of aldosterone effects on electrolyte excretion by actinomycin
D. J.-D. Horisberger and J. Diézi. Institut de Pharmacologie de
1' Université, Lausanne, Switzerland. Administration of aldosterone (A)
to 24-hr adrenalectomized, dexamethasone substituted rats, at doses
providing plasma concentrations of A in the physiological range (ca. 1
nM), results in simultaneous antinatriuresis and kaliuresis occurring 30—
60 mm after starting A infusion. Since it has been reported previously
that A-induced antinatnuresis, but not kaliuresis, was prevented by
actinomycin D (AcD), an inhibitor of protein synthesis at the transcrip-
tion level, we investigated the effects of AcD in our rat model.
Anesthetized, 24-hr adrenalectomized male Wistar rats received, as
glucorticoid substitution, low doses of dexamethasone (plasma conc.
ca. 5 nM). After 2 hr of equilibration, A (I pg/kg iv, then I g/kghr) was
given. AcD (300 pg/kg iv) was injected 30 mm before A. Control groups
(A only, or AcD only, or vehicle alone) were also performed. Clear-
ances of inulin, Na and K were measured during nine 30-mm periods of
urine collection (one before, eight after A administration). The follow-
ing observations were made: (I) Both antinatriuresis and kaliuresis
induced by A were significantly inhibited by AcD. Concomitant
changes of plasma concentrations of Na and K induced by A alone were
also prevented by AcD. (2) Inhibition of A effects by AcD could not be
explained by modifications of glomerular filtration rate, which remained
unaffected by AcD. (3) AcD per se elicited significant natriuresis and
kaliuresis, which should be taken into account when estimating the
interactions between AcD and A. It was concluded that both character-
istic effects of mineralocorticoids on Na and K tubular transport are
prevented by AcD, a finding which favors the suggestion that A effects
on Na and K are linked closely and might depend on the same
mechanisms.
Morphologic aspects of nephronogenesis in organotypic culture. J.
Kazimierczak and J. Diezi. Institut d'Histologie et d'Embryologie and
Institut de Pharmacologie, Lausanne, Switzerland. The development
of mouse metanephric nephron in organotypic culture was studied with
transmission (TEM) and scanning (SEM) electron microscopy. The
kidney of 13-day fetuses of Swiss white mice were cultivated in vitro for
6 days on Nucleopore filter and then processed for TEM and SEM. It
was observed that in the cultured fetal kidney the induction process
persists and that primitive forms of the nephron develop in the same
manner as in vivo. First, the metanephrogenic blastema cells aggregate
around the terminal dilatation of the ureteric bud in a form of a cap from
which the renal vesicles, the primordial nephrons, separate. The vesicle
assumes then a form of an S-shaped structure the lower part of which
differentiates into a double-walled bowl from which the glomerular and
capsular epithelia arise. In the early stages of in vitro glomerulogenesis,
the endothelial and mesangial cells can occasionally be distinguished;
although only the glomerular epithelium continues further differentia-
tion into the podocytes and their foot processes interconnected by an
apparent filtration slit membrane. The vascular and mesangial elements
disappear during glomerulogenesis in vitro, and the podocytes remain
attached at two sides of a very irregular mesoglomerular membrane,
extending from the hilus into the glomerulus. The tubular epithelium is
strikingly less differentiated than the glomerular one, although the
proximal and distal parts of the nephron can be distinguished from each
other by a presence of numerous short microvilli protruding into the
very narrow lumen of the presumed proximal tubule. The thin segments
and the JGA have not been found, and the nephrons are not in any
luminal continuation with the relatively well developed collecting
system.
Four years of experience with CAPD. H. J. Gloor and K. D. Nolph.
University of Missouri Medical Center, Columbia, Missouri. The first
50 patients with end-stage renal disease undergoing continuous ambula-
tory peritoneal dialysis (CAPD) were analyzed with respect to survival,
adherence to CAPD, hospitalization days, peritonitis rate, peritoneal
access problems, and surgical complications. Mean age was 53 years
with a range from 18 to 76. Average length of time on CAPD was 14.3
months per patient. After two years of treatment actuarial patient
survival was 77% but only 48% of the 50 patients continued on CAPD.
However, looking at data since the introduction of dialysate in plastic
bags survival was 85% and adherence to CAPD 63% after 2 years. Total
hospitalization time was 37 days per patient year but only 13 days were
strictly CAPD related. The overall peritonitis rate was 2.4 episodes per
patient year. Since 1979 (bag era) peritonitis dropped to 1.3 episodes per
patient year. Eighty-five double cuff Tenckhoff catheters were inserted
into the abdominal cavity. Fifty-five percent of the inserted catheters
functioned normally after 2 years of observation. Seven patients (14%)
required three or more attempts for successful catheter function.
Common catheter complications were leakage (12x), drainage failures(l4x), and tunnel infections (9x) requiring catheter removal and
replacement. Abdominal herniae occured frequently (13 x) at different
locations. Seven vascular surgeries were carried out on five patients.
Two patients died from perforated diverticuli of the colon. Reviewing
the 4-year experience CAPD was considered as a valuable form of
treatment for end-stage renal disease. Survival and outcome are compa-
rable to hemodialysis. Most CAPD problems are of technical nature
related to peritoneal access, drainage, and maintaining sterility of the
system.
Creatinine clearance studies in newborn infants receiving gentamicin.
G. Wilson, R. Tabin, J.-L. Micheli, and J.-P. Guignard, Service de
Pédiatrie, CHUV, Lausanne, Switzerland. Gentamicin is the aminogly-
coside of choice for the treatment of neonatal infections. Gentamicin
nephrotoxicity has been well documented in adult patients, but not in
newborn infants where it is generally considered as a relatively safe
drug. Creatinine clearance studies were performed in both premature
and term neonates receiving gentamicin at a dose of 5 mI/kg per day.
Nontreated neonates with similar gestational age and birth body weight
were used as controls. The clinical and laboratory parameters like
temperature, blood pressure, plasma electrolytes, acid base balance
and urinary sediment were similar in both groups of treated and
nontreated patients. In preterm newborns (GA = 32.5 weeks) the mean
creatinine clearance was 33.9 ml/min per 1.73 m2 (SD = 6.5) for the
control group and 21.3 mI/mm per 1.73 m2 (SD = 13.4) in the treated
group. The difference, as assessed by the x2 test was not significant (x2
= 2.3, N = 18). In the term-newborns, the mean creatinine clearance
was 46.8 mI/mm per 1.73 m2 (SD = 6.9) in the nontreated patients and
26.0 mI/mm per 1.73 m2 (SD = 7.6) in the treated patients (x2 = 4.0, N =
14, P < 0.01). Fractional excretion of Na was globally higher in preterm
than in term-newborn infants (0.81% vs. 0.51%). FeN was identical in
treated and nontreated premature infants. FeNa was higher in term-
infants receiving gentamicin as compared to controls (0.80% vs. 0.27%)
but the difference was not significant. These results suggest that
gentamicin can depress GFR in newborn infants, the more so in the
more mature neonates. The difference seen in premature and term
neonates could be explained by the relative immaturity and underperfu-
sion of superficial nephrons in premature neonates, at the time when
they were given gentamicin.
Postnatal development of renal function in the newborn rabbit. J.
Cotting and J.-P. Guignard, Service de Pédiatrie, CHUV, Lausanne,
Switzerland. The development of glomerular filtration rate (GFR) has
been studied in newborn rabbits aged 1 to 20 days. Renal clearance
studies were carried out on 51 mechanically-ventilated animals, anes-
thetized with Na pentobarbital. Oxygen-enriched gas mixtures were
used to maintain plasma oxygen tension about 75 mm Hg. Animals were
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infused with a Ringer-mannitol solution at a rate of 25 mI/hr x kg BWt.
Inulin was used as marker of GFR. Birth occurred after 32 days of
gestation. Body weight increased linearly with postnatal age: BWt (g) =
48.9 + 10.2 (day), r = 0.99, P <0.001. Kidney wet weight bore a direct
relationship to body weight: KWt (g) = 0.34 + 0.0175 (g) BWt. Mean
arterial pressure (MAP) also increased progressively with age: MAP
(mm Hg) = 31.4 + 1.66 (day), r = 0.84, P <0.001. During the clearance
study, which lasted 4 hr, blood gases and electrolytes remained stable
with mean values of pH = 7.41 0.007 (saM), PCO2 = 40.3 0.93mm
Hg, P02 = 97 4.5 mm Hg, HCO3 = 25.9 0.48 mmoles/liter, Na =
137 0.8 mmole/liter, K = 3.8 0.15 mmole/liter. Plasma proteins
decreased significantly from 32.2 1.1 to 28.2 0.9 g/liter and
hematocrit from 30 0.9% to 29 0.8%. Mean arterial pressure
remained stable. Urine flow was constant during the study and in-
creased from 133 *l1min x kg BWt on 1st day to 295 l on 20th day.
GFR: from a mean value of 1.4 mI/mm x kg BWt on 1st day, inulin
clearance increased linearly to 6.2 mI/mm x kg BWt on 20th day. GFR
showed a better correlation with postnatal age when weighted by
kidney wet weight: GFR (l/min x g KWt) = 78.9 + 19.1 (day), r =
0.92, P < 0.001. A significant correlation was found between GFR and
mean arterial pressure, at MAP values above 36 mm Hg. Fractional
excretion of Na was elevated at birth and decreased to a value of 1.75
0.3% within 7 days; fractional excretion of K averaged 44.6 4.4%.
The newborn rabbit whose nephrogenesis is complete at 8 days after
birth, appears to be a convenient model for the study of early renal
functional maturation.
Vitamin D replacement therapy in the nephrotic syndrome. B. Haldi-
mann and U. Trechsel. Medizinische Poliklinik and Department of
Pathophysiology, University of Berne, CH-3010 Berne, Switzerland.
Vitamin D depletion and subsequent abnormalities of calcium metabo-
lism have been described in the nephrotic syndrome (NS). On the basis
of an acute oral load, vitamin D requirements to maintain the blood
concentration of 25-hydroxycholecalciferol (25-HCC) within normal
limits have been calculated to be around 20 g of 25-HCC a day. We
report here the effect of long term administration of 25 g of vitamin D3
daily (1000 IU) on the plasma concentrations of 25-HCC and 1,25-
dihydroxycholecalciferol (1 ,25-DHCC) in seven nephrotic patients(four with normal, three with elevated plasma creatinine). Vitamin D
metabolite concentrations were measured at regular intervals. The
mean duration of treatment was 14 weeks (2 weeks to one year).
Results: Plasma levels of 25-HCC increased from 9,6 4.0 (SD) nmoles/
liter (normal range: 23 to 85) before treatment to 33.0 10.8 nmoles/
liter (range: 14.5 to 50.5) under treatment (P < 0.001). During vitamin D
therapy, only 2 of the 14 values were slightly below the lower limit of
the normal range. Before therapy I ,25-DHCC plasma levels were also
decreased: 33.8 17.2 pmoles/liter (normal range 59 to 170). Under
treatment, the 1,25 DHCC levels returned to normal range in the four
patients with normal plasma creatinine. In one case there was an initial
overshot to 319 pmoles/liter; such an excessive production of 1,25-
DHCC has also been reported in the early phase of treatment of
nutritive osteomalacia. In one patient with severe NS, hypermagnese-
mia (1.64 mmoles/liter; normal range 0.70 to 0.95) developed during
vitamin D therapy. Hypermagnesemia in presence of normal renal
function and normal concentrations of vitamin D metabolites was very
surprising and might have depended on an increased tubular reabsorp-
tion of magnesium due to the nephrotic syndrome itself. Conclusions:
The daily dose of 25 jxg of vitamin D3 is adequate to correct the 25-HCC
levels in patients with the nephrotic syndrome. This dose also adequate-
ly corrects the 1 ,25-DHCC levels in patients with good renal function.
The benefit of such a treatment remains to be demonstrated.
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Determination of -glucosidase (3-Gluc) in urine to diagnose kidney
transplant (KT) rejection. J. D. Tgetgel, M. Le Hir, and U. C. Dubach.
Medizinische Univesitäts-Poliklinik, Basel, Switzerland. f3-Gluc is
found in the rat kidney only in the proximal tubule. An increased
activity of 13-Gluc is therefore expected when damage has occurred.
Between January 1980 and February 1981 the f3-Gluc excretion in II
patients, 7 men and 4 women, 27 to 64 years old (average 42 years), was
determined after KT. Method: During the first few days after KT, urine
samples were obtained daily by means of an ureter catheter (UC),
afterwards by a bladder catheter (BC). The 24-hr urine volume was
determined by the UC until it was removed, followed by the BC. At the
same time serum creatinine was determined daily. The 3-Gluc activity
was fluorimetrically measured in dialyzed samples with 4-methyl-
umbiliferyl-3-D-glucopyranoside as substrate and expressed in n units!
ml. Results: (1) In eight patients the highest activity was measured
before the 3rd postoperative day. In one patient the 13-Gluc activity was
never high. Two patients reached peak values only after the 4th
postoperative day; they suffered a predominantly vascular rejection. (2)
Eight patients suffered from an interstitial rejection reaction during the
observation period, accompanied by a clear activity peak of the 3-Gluc
in three cases only. The peak however remained lower than in the short-
lived postoperative peak. Conclusion: The 3-Gluc determination in
urine made possible the revelation of postoperative renal damage of
short duration in the tubular epithelium after KT in 8 out of II patients.
Noteworthy is the detection of the feared vascular form of rejection
reaction, with the aid of the 3-Gluc determination, in the urine of two
patients. However, the interstitial form of rejection is not regularly
demonstrable.
Clinical survey of kidney transplantation in a series of 12 patients with
juvenile-onset insulin-dependent diabetes mellitus. D. Frei, R. D. Gut:-
mann, J. Knaak, D. D. Morehouse, J. Meakins, and C. Mime.
Transplantation Service, Royal Victoria Hosp. and McGill University,
Montréal, Canada. Between January 1, 1971, and December 31, 1980,
l2juvenile-onset insulin-dependent diabetics with uremia underwent 14
kidney transplantations at the Royal Victoria Hospital. The mean age of
the six male and six female recipients was 32.8 years at transplantation.
Nine transplants, including two second transplants, were done from
pretreated nonliving donors and five from living-related donors. Seven
of 12 patients (58%) were alive 11 to 116 months after transplantation.
In two of these seven patients, hemodialysis treatment had to be
resumed after transplantation due to graft failure. Two patients died 41
months and 81 months, respectively, after transplantation with a
functioning graft. Thus, of the 14 transplants to the 12 patients, five
(36%) are still functioning 73, 87, 88, 95, and 116 months after
transplantation. Rejection was the cause of graft loss in all seven cases,
including the two second transplants. Two patients developed recurrent
glomerulosclerosis diagnosed post mortem. Transplantation had benefi-
cial effects on retinopathy, neuropathy, and rehabilitation in all the
patients. But progression of peripheral vascular disease was not de-
layed by transplantation, and amputations had to be done even in 58%
of the patients after transplantation. Recipient age of less than 36 years,
no presensitization with lymphocytotoxic antibodies at transplantation
and absence of acute tubular necrosis during the early post-transplant
period are suggested to be favorable variables in these patients,
whereas HLA matching and source of the donor kidney did not seem to
influence patient or graft survival.
Alive Died
Functioning graft 5 patients (42%) 2 patients (17%)
Hemodialysis treatment 2 patients (17%) 3 patients (25%)
